1 |
Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Stanford, California: Stanford university press, 1959
|
2 |
Antoniazzi F, Zamboni G. Central precocious puberty: current treatment options. Paediatr Drugs 2004;6:211-31
DOI
ScienceOn
|
3 |
Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Antoniazzi F, et al. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol 1999;141:140-4
DOI
|
4 |
Cassio A, Cacciari E, Balsamo A, Bal M, Tassinari D. Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years. Arch Dis Child 1999;81:329-32
DOI
|
5 |
Choi JH. Proper Dosage and Duration of GnRH Agonist Treatment in Central Precocious Puberty. J Korean Soc Pediatr Endocrinol 2006;11:8-14
|
6 |
Seo JY, Yoon IS, Shin CH, Yang SW. The comparison of predicted adult height change and height gain after gonadotropin- releasing hormone agonist and combined growth hormone treatment in girls with idiopathic central precocious puberty. Korean J Pediatr 2006;49:305-11
DOI
|
7 |
Yi KH. Indication of Combined Treatment of GnRH Agonist and GH. J Korean Soc Pediatr Endocrinol 2005;10:24-9
|
8 |
Ahn SY, Yoo JH, Shin CH, Yang SW. The effects of gonadotropin-releasing hormone agonists on final height and its related factors in patients with true precocious puberty. Korean J Pediatr 2004;47:647-55
|
9 |
Yoo SY, Yoo HW. Effects of treatment with long-acting gonadotropin-releasing hormone agonist on somatic growth in patients with central precocious puberty. J Korean Soc Pediatr Endocrinol 1998;3:59-67
|
10 |
Sonis WA, Comite F, Blue J, Prescovitz OH, Rahn CW, Hench KD, et al. Behavior problems and social competence in girls with true precocious puberty. J Pediatr 1985;106: 156-60
DOI
|
11 |
Kaplowitz PB, Oberfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics 1999;104:936-41
DOI
ScienceOn
|
12 |
Lee EJ, Han HS. Growth promoting effect of short-term gonadotropin releasing hormone agonist with or without growth hormone in girls with early puberty. Korean J Pediatr 2007;50:198-204
DOI
ScienceOn
|
13 |
Klein KO, Baron J, Barnes KM, Pescovitz OH, Cutler GB Jr. Use of an ultrasensitive recombinant cell bioassay to determine estrogen levels in girls with precocious puberty treated with a luteinizing hormone-releasing hormone agonist. J Clin Endocrinol Metab 1998;83:2387-9
DOI
|
14 |
Rosenfield RL. Puberty in the female and its disorders. In : Sperling MA, editor. Pediatric endocrinology. 2nd ed. Philadelphia : WB Saunders Co, 2002:455-518
|
15 |
Tanaka T, Hibi I, Kato K, Saito S, Shimizu N, Suwa S, et al. A dose finding study of a super long-acting luteinizing hormone-releasing hormone analog (leuprolide acetate depot, TAP-144-SR) in the treatment of central precocious puberty. The TAP-144-SR CPP Study Group. Endocrinol Jpn 1991;38:369-76
DOI
ScienceOn
|
16 |
Carel JC, Lahlou N, Guazzarotti L, Joubert-Collin M, Roger M, Colle M, et al. Treatment of central precocious puberty with depot leuprorelin. French Leuprorelin Trial Group. Eur J Endocrinol 1995;132:699-704
DOI
|
17 |
Lee SG, Choi WJ, Kim MJ, Kim YH, Jung JA, Hwang IT, et al. The efficacy of modified puberty suppression score by single blood sample for evaluation of GnRH agonist treatment in central precocious puberty. J Korean Soc Pediatr Endocrinol 2005;10:181-7
|
18 |
Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423-41
DOI
|
19 |
Ahn BH, Han HS. Effect of GnRH analogue on predicted adult height in girls with early puberty. Korean J Pediatr 2006;49:552-7
DOI
ScienceOn
|
20 |
Brito VN, Latronico AC, Arnhold IJ, Mendonca BB.A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropindependent precocious puberty in girls. J Clin Endocrinol Metab 2004;89:4338-42
DOI
|
21 |
Lawson ML, Cohen NA. Single sample subcutaneous luteinizing hormone (LH)-releasing hormone (LHRH) stimulation test for monitoring LH suppression in children with central precocious puberty receiving LHRH agonists. J Clin Endocrinol Metab 1999;84:4536-40
DOI
|
22 |
Grumbach MM, Styne DM. Puberty: Ontogeny, neuroendocrinology, physiology, and disorders. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. Williams Textbook of Endocrinology, 10th ed. Philadelphia : WB Saunders Co, 2003:1115-286
|
23 |
Cook JS, Doty KL, Conn PM, Hansen JR. Assessment of depot leuprolide acetate dose-adequacy for central precocious puberty. J Clin Endocrinol Metab. 1992;74:1206-9
DOI
|
24 |
Badaru A, Wilson DM, Bachrach LK, Fechner P, Gandrud LM, Durham E, et al. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab 2006;91:1862-7
DOI
|
25 |
Paul D, Conte FA, Grumbach MM, Kaplan SL. Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years. J Clin Endocrinol Metab 1995;80:546-51
DOI
|
26 |
Rosenfield RL. Selection of children with precocious puberty for treatment with gonadotropin releasing hormone analogs. J Pediatr 1994;124:989-91
DOI
|
27 |
Schoevaart CE, Drop SL, Otten BJ, Slijper FM, Degenhart HJ. Growth analysis up to final height and psychosocial adjustment of treated and untreated patients with precocious puberty. Horm Res 1990;34:197-203
DOI
|
28 |
Bouvattier C, Coste J, Rodrigue D, Teinturier C, Carel JC, Chaussain JL, et al. Lack of effect of GnRH agonists on final height in girls with advanced puberty: a randomized long-term pilot study. J Clin Endocrinol Metab 1999;84: 3575-8
DOI
|
29 |
Witchel SF, Baens-Bailon RG, Lee PA. Treatment of central precocious puberty: comparison of urinary gonadotropin excretion and gonadotropin-releasing hormone (GnRH) stimulation tests in monitoring GnRH analog therapy. J Clin Endocrinol Metab 1996;81:1353-6
DOI
|
30 |
Parker KL, Baens-Bailon RG, Lee PA. Depot leuprolide acetate dosage for sexual precocity. J Clin Endocrinol Metab 1991;73:50-2
DOI
|
31 |
Korean Society of Pediatric Endocrinology. Growth. Pediatric Endocrinology. 2nd ed. Seoul : Kwangmoom, 2004:36-56
|
32 |
Mul D, de Muinck Keizer-Schrama SM, Oostdijk W, Drop SL. Auxological and biochemical evaluation of pubertal suppression with the GnRH agonist leuprolide acetate in early and precocious puberty. Horm Res 1999;51:270-6
DOI
ScienceOn
|